Stage IIIA Ovarian Epithelial Cancer (DBCOND0030394)
Identifiers
- Synonyms
- Not Available
Associated Data
- Indicated Drugs and Targets
- Not Available
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT01982487 Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission treatment 1 / 2 withdrawn NCT02082470 Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer No drug interventions supportive_care Not Available completed NCT01846520 Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers No drug interventions supportive_care Not Available completed NCT01764802 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer No drug interventions supportive_care 2 completed NCT01536054 Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer treatment 1 completed NCT00335998 Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies treatment 1 completed NCT01927393 Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer No drug interventions supportive_care Not Available withdrawn NCT02122185 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer treatment 2 active_not_recruiting NCT00388037 Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer treatment 2 completed NCT00083122 Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer treatment 2 completed NCT00063895 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck treatment 1 / 2 completed